Printed From:

Healthcare professionals have chosen Lantus® for over 18 years1


Lantus® was evaluated for 52 weeks in adults with type 2 diabetes poorly controlled with OADs

Safety results

Study Design

A 52-week randomized study (N=570) designed to compare efficacy and safety of Lantus® plus OADs vs NPH plus OADs in patients with type 2 diabetes poorly controlled with OADs. Patients were randomized to either Lantus® (n=289) or NPH (n=281) at bedtime to reach a target FPG of <120 mg/dL. OADs were continued. Initial insulin dose and titration schedule were left to the discretion of the individual investigators. Primary endpoint was change in A1C.


In a pediatric clinical study, children and adolescents with T1DM had a higher incidence of severe symptomatic hypoglycemia in the 2 treatment groups (Lantus® or NPH) compared to adult trials with type 1 diabetes.

  • Baseline A1C was 8.48% and 8.81% for the Lantus® and NPH groups, respectively
  • The relative change in A1C at 28 weeks was +0.28% for the Lantus® group (n=174) and +0.27% for the NPH group (n=175)

Once-daily pediatric dosing

In the same pediatric trial

  • 35% of patients on NPH needed to inject twice as often as patients on once-daily Lantus® in order to maintain comparable A1C levels

Safety results

Study Design

A 28-week, randomized, open-label, multicenter study of 349 patients with type 1 diabetes (aged 6-15) who received once-daily Lantus® (n=174) or once- or twice-daily NPH (n=175) in combination with regular human insulin as the mealtime insulin. The primary efficacy measure was mean change in A1C from baseline.

aSymptomatic hypoglycemia was defined as any event with clinical symptoms that could be confirmed by BG level <50 mg/dL.

bSevere hypoglycemia was defined as an event with symptoms consistent with hypoglycemia in which the subjects required the assistance of another person and which was associated with a BG level <50 mg/dL or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration. This definition is consistent with that used in the Diabetes Control and Complications Trial.